RL
LYEL icon

RPO LLC’s Lyell Immunopharma LYEL Stock Holding History

RPO LLC’s Portfolio LYEL Stock Details LYEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-3,319
Closed -$42.5K – 73
2024
Q4 		$42.5K Buy
+3,319
New +$65.8K 0.04% 67
2024
Q1 		– Sell
-987
Closed -$38.3K – 77
2023
Q4 		$38.3K Buy
+987
New +$35.5K 0.06% 85

Other funds holding LYEL

MM
MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
OPL
Orland Properties Ltd Road Town, Tortola, British Virgin Islands $267M AUM 5.05% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $271M AUM 309.87% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

RPO LLC's LYEL Position: Q1 2025 in Review

RPO LLC sold out of Lyell Immunopharma (LYEL) in Q1 2025, closing a stake of 3,319 shares — an estimated $42.5K sold.

RPO LLC first reported a position in LYEL in Q4 2023 and held it in 2 quarters. The position peaked at $42.5K in Q4 2024. 112 funds tracked by Wall St. Rank hold LYEL as of Q1 2025.

  • RPO LLC reported no remaining Lyell Immunopharma position as of Q1 2025 after selling out during the quarter.
  • RPO LLC sold 3,319 Lyell Immunopharma shares in Q1 2025, an estimated $42.5K.
  • RPO LLC first reported a position in Lyell Immunopharma in Q4 2023 and held it in 2 quarters.
  • RPO LLC's Lyell Immunopharma position peaked at $42.5K in Q4 2024.
  • 112 funds tracked by Wall St. Rank held Lyell Immunopharma as of Q1 2025.

Based on RPO LLC's 13F filing for Q1 2025, filed 13 May 2025.